1. Garg A: Acquired and inherited lipodystrophies. N Engl J Med 350:1220-1234, 2004
2. Garg A: Lipodystrophies. Am J Med 108:143-152, 2000
3. Garg A, Misra A: Lipodystrophies: Rare disorders causing metabolic syndrome. Endocrinol Metab Clin North Am 33:305-331, 2004
4. Garg A, Wilson R, Barnes R, et al: A gene for congenital generalized lipodystrophy maps to human chromosome 9q34. J Clin Endocrinol Metab 84:3390-3394, 1999
5. Agarwal AK et al: AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nat Genet 31:21-23, 2002
6. Magre J et al: Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nat Genet 28:365-370, 2001
7. Kim CA et al: Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy. J Clin Endocrinol Metab 93:1129-1134, 2008
8. Hayashi YK et al: Human PTRF mutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy. J Clin Invest 119:2623-2633, 2009
9. Agarwal AK, Garg A: Congenital generalized lipodystrophy: Significance of triglyceride biosynthetic pathways. Trends Endocrinol Metab 14:214-221, 2003
10. Szymanski KM et al: The lipodystrophy protein seipin is found at endoplasmic reticulum lipid droplet junctions and is important for droplet morphology. Proc Natl Acad Sci U S A 104:20890-20895, 2007
11. Fei W et al: Fld1p, a functional homologue of human seipin, regulates the size of lipid droplets in yeast. J Cell Biol 180:473-482, 2008
12. Payne
VA et al: The human lipodystrophy gene BSCL2/seipin may be essential for normal adipocyte differentiation.
Diabetes 57:2055-2060, 2008
13. Agarwal AK et al: Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy. J Clin Endocrinol Metab 88:4840-4847, 2003
14. Van Maldergem L et al: Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy. J Med Genet 39:722-733, 2002
15. Fleckenstein JL et al: The skeleton in congenital, generalized lipodystrophy: Evaluation using whole-body radiographic surveys, magnetic resonance imaging and technetium-99m bone scintigraphy. Skeletal Radiol 21:381-386, 1992
16. Simha V, Garg A: Phenotypic heterogeneity in body fat distribution in patients with congenital generalized lipodystrophy caused by mutations in the AGPAT2 or seipin genes. J Clin Endocrinol Metab 88:5433-5437, 2003
17. Rajab A et al: Fatal cardiac arrhythmia and long-QT syndrome in a new form of congenital generalized lipodystrophy with muscle rippling (CGL4) due to PTRF-CAVIN mutations. PLoS Genet 6:e1000874, 2010
18. Shastry S et al: Congenital generalized lipodystrophy, type 4 (CGL4) associated with myopathy due to novel PTRF mutations. AM J Med Genet152A(9):2245-2253, 2010
19. Cao H, Hegele RA: Nuclear lamin A/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy. Hum Mol Genet 9:109-112, 2000
20. Shackleton S et al: LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet 24:153-156, 2000
21. Speckman RA et al: Mutational and haplotype analyses of families with familial partial lipodystrophy (Dunnigan variety) reveal recurrent missense mutations in the globular C-terminal domain of lamin A/C. Am J Hum Genet 66:1192-1198, 2000
22. Peters JM et al: Localization of the gene for familial partial lipodystrophy (Dunnigan variety) to chromosome 1q21–22. Nat Genet 18:292-295, 1998
23. Agarwal AK, Garg A: A novel heterozygous mutation in peroxisome proliferator-activated receptor-g gene in a patient with familial partial lipodystrophy. J Clin Endocrinol Metab 87:408-411, 2002
24. Hegele RA et al: PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes 51:3586-3590, 2002
25. Semple RK, Chatterjee VK, O'Rahilly S: PPAR gamma and human metabolic disease. J Clin Invest 116:581-589, 2006
26. George S et al: A family with severe
insulin resistance and diabetes due to a mutation in AKT2.
Science 304:1325-1328, 2004
27. Gandotra S et al. Perilipin deficiency and autosomal dominant partial lipodystrophy. N Engl J Med 364:740-748, 2011
28. Dunnigan MG et al: Familial lipoatrophic diabetes with dominant transmission. A new syndrome. Q J Med 43:33-48, 1974
29. Garg A, Peshock RM, Fleckenstein JL: Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety). J Clin Endocrinol Metab 84:170-174, 1999
30. Garg A. Gender differences in the prevalence of metabolic complications in familial partial lipodystrophy (Dunnigan variety). J Clin Endocrinol Metab 85:1776-1782, 2000
31. Garg A, Speckman RA, Bowcock AM: Multisystem dystrophy syndrome due to novel missense mutations in the amino-terminal head and alpha-helical rod domains of the lamin A/C gene. Am J Med 112:549-555, 2002
32. Garg A et al: Phenotypic heterogeneity in patients with familial partial lipodystrophy (Dunnigan variety) related to the site of mis-sense mutations in Lamin A/C (LMNA) gene. J Clin Endocrinol Metab 86:59-65, 2001
33. Novelli G et al: Mandibuloacral dysplasia is caused by a mutation in LMNA-encoding lamin A/C. Am J Hum Genet 71:426-431, 2002
34. Agarwal AK et al: Zinc metalloproteinase, ZMPSTE24, is mutated in mandibuloacral dysplasia. Hum Mol Genet 12:1995-2001, 2003
35. Simha V, Garg A: Body fat distribution and metabolic derangements in patients with familial partial lipodystrophy associated with mandibuloacral dysplasia. J Clin Endocrinol Metab 87:776-785, 2002
36. Simha V et al: Genetic and phenotypic heterogeneity in patients with mandibuloacral dysplasia-associated lipodystrophy. J Clin Endocrinol Metab 88:2821-2824, 2003
37. Agarwal AK et al: Focal segmental glomerulosclerosis in patients with mandibuloacral dysplasia due to zinc metalloproteinase deficiency. J Investig Med 54:208-213, 2006
38. Ahmad Z et al: Early onset mandibuloacral dysplasia due to compound heterozygous mutations in ZMPSTE24. Am J Med Genet 152A(11):2703-2710, 2010
39. Rubio-Cabezas O et al: Partial lipodystrophy and
insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEC.
EMBO Mol Med 1:280-287, 2009
40. Garg A et al: Atypical progeroid syndrome due to heterozygous missense LMNA mutations. J Clin Endocrinol Metab 94:4971-4983, 2009
41. Merideth MA et al: Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med 358:592-604, 2008
42 Agarwal AK et al. PSMB8 encoding the ß5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome. Am J Hum Genet 87:866-872, 2010
43. Liu et al. Mutations in PSMB8 cause CANDLE syndrome and evidence of genetic and phenotypic heterogeneity. Arthritis Rheum. In press, 2011
44a. Kitamura A, et al. A mutation in the immunoproteasome subunit PSMB8 causes autoinflammation and lipodystrophy in humans. J Clin Invest. 2011 Oct 3;121(10):4150-60
44b. Arima K et al. Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. Proceedings of the National Academy of Sciences of the United States of America. Proc Natl Acad Sci U S A 2011 Sep 6;108(36):14914-9
44c. Rivett, A.J., and Hearn, A.R. (2004). Proteasome function in antigen presentation: Immunoproteasome complexes, peptide production, and interactions with viral proteins. Curr. Protein Pept. Sci. 5,153-161
45. Shastry S et al: A novel syndrome of mandibular hypoplasia, deafness and progeroid features associated with lipodystrophy, undescended testes and male hypogonadism. J Clin Endocrinol Metab 95(10):E192– E197, 2010 [Epub Jul 14, 2010]
46. Torrelo et al. Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature. J Am Acad Dermatol 62:489-95, 2010
47. Garg A et al: An autosomal recessive syndrome of joint contractures, muscular atrophy, microcytic anemia, and panniculitis-associated lipodystrophy. J Clin Endocrinol Metab 95(9):E58-E63, 2010
48. Sensenbrenner JA, Hussels IE, Levin LS: CC – A low birthweight syndrome, Rieger syndrome. Birth Defects 11:423-426, 1975
49. Gorlin RJ et al: Rieger anomaly and growth retardation (The S-H-O-R-T Syndrome). Birth Defects 11:46-48, 1975
50. O'Neill B et al: Body fat distribution and metabolic variables in patients with neonatal progeroid syndrome. Am J Med Genet A 143:1421-1430, 2007
51. Misra A, Peethambaram A, Garg A: Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: Report of 35 cases and review of the literature. Medicine (Baltimore) 83:18-34, 2004
52. Misra A, Garg A: Clinical features and metabolic derangements in acquired generalized lipodystrophy: Case reports and review of the literature. Medicine 82:129-146, 2003
53. Chen D, Misra A, Garg A: Lipodystrophy in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab 87:4845-4856, 2002
54. Mathieson PW et al: Complement-mediated adipocyte lysis by nephritic factor sera. J Exper Med 177:1827-1831, 1993
55. Hudon SE et al: HIV-protease inhibitors block the enzymatic activity of purified Step 24. Biochem Biophys Res Commun 374:365-368, 2008
56. Bastard JP et al: Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and
insulin resistance.
Lancet 359:1026-1031, 2002
57. Murata H, Hruz PW, Mueckler M: The mechanism of
insulin resistance caused by HIV protease inhibitor therapy.
J Biol Chem 275:20251-20254, 2000
58. Carr A et al: A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 14:F25-F32, 2000
59. Grinspoon S, Carr A: Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 352:48-62, 2005
60. Haque WA et al: Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab 87:2395-2398, 2002
61. Hegele RA: Premature atherosclerosis associated with monogenic
insulin resistance.
Circulation 103:2225-2229, 2001
62. Hennekam RC: Hutchinson-Gilford progeria syndrome: Review of the phenotype. Am J Med Genet A 140:2603-2624, 2006
63. Agarwal AK et al: Severe mandibuloacral dysplasia-associated lipodystrophy and progeria in a young girl with a novel homozygous Arg527Cys LMNA mutation. J Clin Endocrinol Metab 93:4617-4623, 2008
64. Sturm LP et al: A systematic review of permanent and semipermanent dermal fillers for HIV-associated facial lipoatrophy. AIDS Patient Care STDS 23:699-714, 2009
65. Arioglu E et al: Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 133:263-274, 2000
66. Savage DB et al: Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-g. Diabetes 52:910-917, 2003
67. Oral EA et al: Leptin-replacement therapy for lipodystrophy. N Engl J Med 346:570-578, 2002
68. Simha V et al: Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy. Diabetes Care 26:30-35, 2003
69. Park JY et al: Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy. Metabolism 56:508-516, 2007
70. Carr A et al: HIV protease inhibitor substitution in patients with lipodystrophy: A randomized, controlled, open-label, multicentre study. AIDS 15:1811-1822, 2001